Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human

References

• Ahr HJ, Krause HP, Siefert HM, et al. (1988). Pharmacokinetics of nisoldipine. I Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. Arzneimittel-Forschung 38:1093–8
   PubMed Web of Science ®Google Scholar
• Bäärnhielm C, Dahlbäck H, Skånberg I. (1986). In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol Toxicol 59:113–22
   PubMedGoogle Scholar
• Beconi MG, Reed JR, Teffera Y, et al. (2007). Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Disp 35:525–32
   PubMed Web of Science ®Google Scholar
• Briem S, Martinsson S, Bueters T, Skoglund E. (2007). Combined approach for high-throughput preparation of plasma samples from exposure studies. Rapid Commun Mass Spectrom 21:1965–72
   PubMed Web of Science ®Google Scholar
• Bueters T, Dahlström J, Kvalvågnaes K, et al. (2011). High-throughput analysis of standardized pharmacokinetic studies in the rat using sample pooling and UPLC-MS/MS. J Pharm Biomed Anal 55:1120–6
   PubMed Web of Science ®Google Scholar
• Cao X, Gibbs ST, Fang L, et al. (2006). Why it is challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675–86
   PubMed Web of Science ®Google Scholar
• Carlos MA, Du Souich P, Carlos R, et al. (2002). Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. J Pharm Sci 91:1627–38
   PubMed Web of Science ®Google Scholar
• Chen M, Xu D, Hu X-L, Wang H. (2008). Effects of liver fibrosis on verapamil pharmacokinetics in rats. Clin Exp Pharmacol Physiol 35:287–94
   PubMed Web of Science ®Google Scholar
• Chiou WL, Barve A. (1998). Linear correlation of the fraction of oral dose absorbed of 64 drugs between human and rats. Pharm Res 15:1792–5
   PubMed Web of Science ®Google Scholar
• Chiou WL, Buehler PW. (2002). Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm Res 19:868–74
   PubMed Web of Science ®Google Scholar
• Cho YA, Choi JS, Burm JP. (2011). Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of p-glycoprotein and CYP3A4 inhibition by baicalein. Pharmacol Rep 63:1066–73
   PubMed Web of Science ®Google Scholar
• Choi J-S, Piao Y-L, Han H-K. (2006). Pharmacokinetic interaction between fluvastatin and diltiazem in rats. Biopharm Drug Disp 27:437–41
   PubMed Web of Science ®Google Scholar
• Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. (2010). Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the Advanced Dissolution, Absorption, Metabolism (ADAM) model. Curr Drug Metab 11:716–29
   PubMed Web of Science ®Google Scholar
• De Buck SS, Sinha VK, Fenu LA, et al. (2007). The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Disp 35:649–59
   PubMed Web of Science ®Google Scholar
• Dostert P, Benedetti MS, Pogessi I. (1997). Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 7:S23–35
   PubMed Web of Science ®Google Scholar
• Durand A, Thenot JP, Bianchetti G, Morselli PL. (1992). Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab Rev 24:239–66
   PubMed Web of Science ®Google Scholar
• Fagerholm U. (2007). Prediction of human pharmacokinetics – gastrointestinal absorption. J Pharm Pharmacol 59:905–16
   PubMed Web of Science ®Google Scholar
• Fan J, Chen S, Chow EC, Pang KS. (2010). PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr Drug Metab 11:743–61
   PubMed Web of Science ®Google Scholar
• Fisher MB, Labissiere G. (2007). The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective. Curr Drug Metab 8:694–9
   PubMed Web of Science ®Google Scholar
• Foster RT, Jamali F. (1988). Stereoselective pharmacokinetics of ketoprofen in the rat: influence of route of administration. Drug Metab Disp 16:623–6
   PubMed Web of Science ®Google Scholar
• Gaillot J, Heusse D, Hougton GW, et al. (1983). Pharmacokinetics and metabolism of zopiclone. Pharmacology 27:76–91
   PubMed Web of Science ®Google Scholar
• Galetin A, Gertz M, Houston JB. (2008). Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions. Expert opin Drug Metab Toxicol 4:909–22
   PubMed Web of Science ®Google Scholar
• Galetin A, Houston JB. (2006). Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318:1220–9
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonell MC, Granero L, Torres-Molina F, et al. (1994). Non-linear pharmacokinetics of cefadroxil in the rat. Drug Metab Disp 21:215-7
   Web of Science ®Google Scholar
• Gertz M, Harrison A, Houston JB, Galetin A. (2010). Prediction of human intestinal first-pass metabolism of 25 CYP3A4 substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147–58
   PubMed Web of Science ®Google Scholar
• Gertz M, Houston JB, Galetin A. (2011). Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos 39:1633–44
   PubMed Web of Science ®Google Scholar
• Grass GM, Sinko PJ. (2002). Physiologically-based pharmacokinetic simulation modeling. Adv Drug Deliv Rev 54:433–51
   PubMed Web of Science ®Google Scholar
• Grundy JS, Eliot LA, Foster RT. (1997). Extrahepatic first-pass metabolism of nifedipine in the rat. Biopharm Drug Disp 18:509–22
   PubMed Web of Science ®Google Scholar
• Hallifax D, Foster JA, Houston JB. (2010). Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 27:2150–61
   PubMed Web of Science ®Google Scholar
• Hatley O, Jones C, Galetin A, Rostami-Hodjegan A. (2011). Methodology optimization in intestinal microsome preparation: implications for scaling approaches? AAPS Annual Meeting and Exposition; Oct 23–27; Washington DC, USA.
   Google Scholar
• Hellriegel ET, Bjornsson TD, Hauck WW. (1996). Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 60:601–7
   PubMed Web of Science ®Google Scholar
• Helton DR, Osborne DW, Pierson SK, et al. (2000). Pharmacokinetic profiles in rats after intravenous, oral, or dermal administration of dapsone. Drug Metab Disp 28:925–9
   PubMed Web of Science ®Google Scholar
• Higuchi S, Shiobara Y. (1980). Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica 10:447–54
   PubMed Web of Science ®Google Scholar
• Hirunpanich V, Katagi J, Sethabouppha B, Sato H. (2006). Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporine in rats. Drug Metab Disp 34:305–10
   PubMed Web of Science ®Google Scholar
• Howell SR, Hicks DR, Scatina JA, Sisenwine SF. (1994). Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Xenobiotica 24:315–27
   PubMed Web of Science ®Google Scholar
• Hui Y-H, Huang NH, Ebbert L, et al. (2007). Pharmacokinetic comparisons of tail-bleeding with cannula- or retro-orbital bleeding techniques in rats using six marketed drugs. J Pharmacol Toxicol Meth 56:256–64
   PubMedGoogle Scholar
• Jamei M, Turner D, Yang J, et al. (2009). Population-based mechanistic predictions of oral drug absorption. AAPS J 11:225–37
   PubMed Web of Science ®Google Scholar
• Jang SH, Lee MH, Lee MG. (1994). Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive wistar rats. J Pharm Sci 83:810–14
   PubMed Web of Science ®Google Scholar
• Jeong EJ, Liu Y, Lin H, Hu M. (2005). Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785–94
   PubMed Web of Science ®Google Scholar
• Kadono K, Akabane T, Tabata K, et al. (2010). Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab Dispos 38:1230–7
   PubMed Web of Science ®Google Scholar
• Kato M, Chiba K, Hisaka A, et al. (2003). The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein – quantitative analysis based on information from the literature. Drug Metab Pharmacokin 18:365–72
   PubMedGoogle Scholar
• Kim EJ, Han KS, Lee MG. (2000). Gastrointestinal first-pass effect of furosemide in rats. J Pharm Pharmacol 52:1337–43
   PubMed Web of Science ®Google Scholar
• Kivistö KT, Grisk O, Hofmann U, et al. (2005). Disposition of oral and intravenous pravastatin in mrp2-deficient TR-rats. Drug Metab Disp 33:1593–6
   PubMed Web of Science ®Google Scholar
• Komura H, Iwaki M. (2011). In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences. Drug Metab Rev 43:476–98
   PubMed Web of Science ®Google Scholar
• Koudriakova T, Iatsimirskaia E, Tulebaev S, et al. (1996). In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. J Pharmacol Exp Ther 279:1300–9
   PubMed Web of Science ®Google Scholar
• Lee DY, Lee I, Lee MG. (2007). Pharmacokinetics of omeprazole after invenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. Int J Pharmaceut 330:37–44
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee MG, Kim ND. (1994). Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. J Pharmacokin Biopharmaceut 22:1–17
   PubMedGoogle Scholar
• Lennernäs H. (2007). Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr Drug Metab 8:645–57
   PubMed Web of Science ®Google Scholar
• Lin JH, Chiba M, Baillie TA. (1999). Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135–57
   PubMed Web of Science ®Google Scholar
• Lindahl A, Sjöberg Å, Bredberg U, et al. (2004). Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. Mol Pharmaceut 1:347–56
   PubMed Web of Science ®Google Scholar
• Mandema JW, Gubbens-Stibbe JM, Danhof M. (1991). Stability and pharmacokinetics of flumazenil in the rat. Psychopharmacology 103:384–7
   PubMed Web of Science ®Google Scholar
• Mandema JW, Tukker E, Danhof M. (1991). Pharmacokinetic-pharmacodynamic modeling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol 102:663–8
   PubMed Web of Science ®Google Scholar
• Mattiuz EL, Ponsler D, Barbuch RJ, et al. (2003). Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fisher 344 rat and Beagle dog. Drug Metab Disp 31:88–97
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Collington J, Austin RP, Riley RJ. (2007). Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 8:463–79
   PubMed Web of Science ®Google Scholar
• Mroszczak EJ, Lee FW, Combs D, et al. (1987). Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. Drug Metab Disp 15:618–26
   PubMed Web of Science ®Google Scholar
• Nishimuta H, Sato K, Yabuki M, Komura S. (2011). Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Drug Metab Pharmacokinet 26:592–601
   PubMed Web of Science ®Google Scholar
• Nomeir AA, Morrison R, Prelusky D, et al. (2009). Estimation of the extent of oral absorption in animals from oral and intravenous pharmacokinetic data in drug discovery. J Pharmaceut Sci 98:4027–38
   PubMed Web of Science ®Google Scholar
• Påhlman I, Kankaanranta S, Palmer L. (2001). Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Arzneimittel-Forschung 51:134–44
   PubMed Web of Science ®Google Scholar
• Riley RJ, McGinnity DF, Austin RP. (2005). A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Disp 33:1304–11
   PubMed Web of Science ®Google Scholar
• Sano H, Sato H, Furuta S, et al. (1991). Pharmacokinetics of nizatidine in dogs and rats. Xenobiotica 21:1257–64
   PubMed Web of Science ®Google Scholar
• Scatina JA, Kimmel HB, Weinstein V, et al. (1990). Species differences in the pharmacokinetics of recainam, a new anti-arrhythmic drug. Biopharm Drug Disp 11:445–61
   PubMed Web of Science ®Google Scholar
• Segura J, Borja L, Bakke OM. (1976). Pharmacokinetics of sulpiride after oral and intravenous administration in the rat and the dog. Arch Int Pharmacodyn 223:88–95
   PubMedGoogle Scholar
• Siefert HM, Domdey-Bette A, Henninger K, et al. (1999). Pharmacokinetics of 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mamalian species. J Antimicrobiol Chemother 43:69–76
   PubMed Web of Science ®Google Scholar
• Sietsema WK. (1989). The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol 27:179–211
   PubMedGoogle Scholar
• Shayeganpour A, Hamdy DA, Brocks DR. (2008). Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone. Biopharm Drug Disp 29:159–66
   PubMed Web of Science ®Google Scholar
• Shibata N, Gao W, Okamoto H, et al. (2002). Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model. J Pharmaceut Sci 91:680–9
   PubMed Web of Science ®Google Scholar
• Shibata Y, Takahashi H, Ishii Y. (2000). A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab Disp 28:1518–23
   PubMed Web of Science ®Google Scholar
• Shin HS, Bae SK, Lee MG. (2006). Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects. Int J Pharmaceut 320:64–70
   PubMed Web of Science ®Google Scholar
• Smith DA, Rasmussen HS, Stopher DA, Walker DK. (1992). Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 22:709–19
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck A-K, Afzelius L, Prusis P, et al. (2010). Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 40:637–49
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck A-K, Jones C, Ferguson D, et al. (2012). Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica 42:841–53
   PubMed Web of Science ®Google Scholar
• Tachibana T, Kato M, Takakno J, Sugiyama Y. (2010). Predicting drug–drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Curr Drug Metab 11:762–77
   PubMed Web of Science ®Google Scholar
• Takahashi M, Washio T, Suzuki N, et al. (2009). The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and human. J Pharm Sci 98:4343–53
   PubMed Web of Science ®Google Scholar
• Thomas VH, Bhattachar S, Hitchingham L, et al. (2006). The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol 2:591–608
   PubMed Web of Science ®Google Scholar
• Thomsen AE, Christensen MS, Bagger MA, Steffansen B. (2004). Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells. Eur J Pharm Sci 23:319–25
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof EG, De Graaf IAM, Groothuis GMM. (2007). In vitro methods to study intestinal drug metabolism. Curr Drug Metab 8:658–75
   PubMed Web of Science ®Google Scholar
• Varma MVS, Obach RS, Rotter C, et al. (2010). Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem 53:1098–108
   PubMed Web of Science ®Google Scholar
• Wang Y, Roy A, Sun L, Lau CE. (1999). A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Disp 27:855–9
   PubMed Web of Science ®Google Scholar
• Ward KW, Nagilla R, Jolivette LJ. (2005). Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. Xenobiotica 35:191–210
   PubMed Web of Science ®Google Scholar
• Widman M, Nilsson LB, Bryske B, Lundström J. (1993). Disposition of remoxipride in different species. Species differences in metabolism. Arzneimittel-Forschung 43:287–97
   PubMed Web of Science ®Google Scholar
• Yamasaki H, Tabata S. (1993). Sex difference in pharmacokinetics of the novel sulfonylurea antidiabetic glimepiride in rats. Arzneimittel-Forschung 43:1317–21
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Rowland Yeo K, et al. (2007). Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676–84
   PubMed Web of Science ®Google Scholar
• Yang SH, Lee MG. (2007). Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability. Int J Pharmaceut 332:17–23
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang C, Liu Q, et al. (2010). Pharmacokinetic interaction between JBP485 and cephalexin in rats. Drug Metab Disp 38:930–8
   PubMed Web of Science ®Google Scholar
• Zhao YH, Abraham MH, Joelle L, et al. (2003). Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur J Med Chem 38:233–43
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tao T, Wu J, et al. (2008). Pharmacokinetics of tramadol in rat plasma and cerebrospinal fluid after intranasal administration. J Pharmacy Pharmacol 60:1149–54
   PubMed Web of Science ®Google Scholar